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Abstract
Mutations that increase activity of Sir2 (silent information regulator 2) are associated with extended lifespan of yeast, fruit
flies and worms. SIRT1, the human homolog of Sir2, that controls numerous physiological processes including the glucose
metabolism, is considered a candidate gene for predicting variation in human lifespan. Whereas the role of Sir2 has been
extensively investigated in model organisms, less is known about the relation between SIRT1 and lifespan in humans. In the
current study we included 1,390 subjects from a general population-based cohort with 18 years of follow-up to investigate
associations between variation in single nucleotide polymorphisms (SNPs) in the SIRT1 gene and human survival.
Additionally in 535 male subjects with available data we investigated associations between SIRT1 and glucose tolerance.
Carriers of the minor allele of rs12778366 had a significantly reduced mortality risk compared to the wild types: Hazard Ratio
0.69 (95% CI 0.50 to 0.96; p = 0.025). The directions of the effect were the same in females and males, never and ever
smokers and the effect was significantly protective in overweight/obese subjects. Carriers of the minor allele of SNP
rs12778366 had better glucose tolerance indicated by 0.34 mmol/l lower glucose levels compared to wild type subjects
(p = 0.03). This study shows that SIRT1 affects human long-term survival and therefore may be an important factor in
modulating lifespan not only in lower organisms, but also in humans.
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Introduction
In the ongoing quest to uncover factors that increase longevity,
sirtuins have attracted scientific and public interest for the past
decades [1]. Initially, overexpression of the silent information
regulator Sir2, nicotinamide adenine dinucleotide (NAD+)-depen-
dent histone deacetylase, has shown a beneficial effect on lifespan
in budding yeast (Saccharomyces cerevisae) [2]. Subsequently, the
experiments performed in worms (Caenorhabditis elegans) and flies
(Drosophila melanogaster) [3,4] confirmed favorable properties of Sir2,
signifying the importance of sirtuins as longevity genes. Since a
more recent report showed an absence of effects of Sir2
overexpression on lifespan in C.elegans and Drosophila [5], a debate
about the role of sirtuins in lifespan prolongation has arisen [1].
Therefore more studies are needed to elucidate the impact of
sirtuins on lifespan, especially in humans. Out of seven identified
mammalian homologues, sirtuin 1 (SIRT1) is the most closely
related to Sir2 [6]. SIRT1 influences the activity of various
transcription factors, including forkhead-box transcription factors
(FOXOs), peroxisome proliferator-activated receptor c (PPAR c)
and nuclear factor-kB (NF-kB) in target tissues resulting in
enhanced gluconeogenesis and repressed glycolysis in the liver,
reduction of adipogenesis in adipose tissue, and increased release
of insulin in pancreatic beta cells [7]. SIRT1 controls adiponectin
levels, inflammatory processes, gluconeogenesis, and levels of
reactive oxygen species that together may lead to the development
of insulin resistance [8]. Overexpression of SIRT1 or using SIRT1
activators improves glucose homeostasis and insulin sensitivity in
mice [8–11]. Therefore partly the effect of SIRT1 on longevity
may be exerted via its association with insulin signaling, which has
been proven to extend lifespan by 18% in fat-specific insulin
receptor knockout (FIRKO) mice [12]. Furthermore, SIRT1 is
required for a normal response to caloric restriction that causes
many changes in glucose metabolism and increases lifespan [13].
In humans, during the last years polymorphisms in SIRT1 have
been investigated in a context of metabolism and have been
associated with BMI and risk of obesity [14–17], acute insulin
response in Pima Indians [18], body fat and blood pressure in
Japanese [19], basal energy expenditure and respiratory quotient
[20], and with diabetes risk in interaction with prenatal exposure
to famine [21]. The few studies that investigated SNPs in SIRT1 in
relation to human lifespan or mortality did not find any
associations [22–25].
Given the fact that near 30% of the individual variance in life
expectancy is genetically determined [26] and the specific genetic
determinants of human lifespan still remain largely unknown,
SIRT1, as a metabolic master switch [7], may be considered a
candidate gene for predicting variation in human lifespan. The
Vlagtwedde/Vlaardingen cohort offers the unique opportunity to
investigate the role of SIRT1 in long-term survival, because
subjects included in the current study were followed up for 18
years. Since SIRT1 modulates a range of cellular processes
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e58636
involved in maintaining glucose homeostasis [27], we additionally
investigated SIRT1 polymorphisms and glucose tolerance.
Methods
Ethics Statement
The study protocol was approved by the local university medical
hospital ethics committee, University of Groningen, University
Medical Center Groningen, The Netherlands and all participants
gave their written informed consent. In 1984, the Committee on
Human Subjects in Research of the University of Groningen
reviewed the study and affirmed the safety of the protocol and
study design.
Study population
We studied 1,390 subjects of the Vlagtwedde/Vlaardingen
cohort participating in the last survey in 1989/1990 [28]. This
general population-based cohort of white individuals of Dutch
descent started in 1965 and has been followed for 25 years. The
main focus of the study was on respiratory health. Surveys (median
number of 7 per subject, range 1–8) were performed every 3 years,
during which information was collected on smoking status, age,
sex and respiratory symptoms by the Dutch version of the British
Medical Council standardized questionnaire, BMI was deter-
mined, spirometry was performed and and the number of
eosinophils in peripheral blood was measured. The vital status of
all participants in the study on December 31, 2008 was assessed.
Causes of death were coded according to the International
Classification of Diseases (ICD) and obtained from the Statistics
Netherlands (The Hague). In order to avoid bias and provide true
associations, the external causes of death (i.e. suicides, homicides,
traffic accidents etc.) were excluded from the analyses, (ICD-9:
codes$800 and in ICD-10: codes $S00).
Blood samples
In 1989/1990 neutrophil depots from peripheral blood samples
were collected and stored at –20uC. In 2003–2004 DNA was
extracted from these samples with a QIAamp DNA blood mini kit
(Qiagen, Hilden, Germany) and checked for purity and concen-
tration with a NanoDrop ND-1000 UV–Vis spectrophotometer
(NanoDrop Technologies, Wilmington, DE) [28].
SNP Selection and Genotyping
Four SNPs (rs12778366, rs10823108, rs7069102 and
rs2273773), that tag all 21 SNPs in SIRT1 and its 5 kb up-/
downstream region with r2.0.8 and Minor Allele Frequency.5%
(based on the HapMap release 23a/March 2008) were genotyped
by K-Bioscience Ltd (UK) [29]. Since rs10823108 and rs2273773
were in complete linkage disequilibrium (r2 = 1.0, Figure S1) in our
study population, only rs2273773 was analyzed.
Table 1. Characteristics of participants at visit 1989/1990 by vital status on Dec 31st, 2008.
Status on 31-12-2008 Alive Dead p value
Number (%) 1087 (78.2) 270 (19.4)
Males, n (%) 525 (48.3) 166 (61.5) 0.000
Age, median (range) 49.4 (36.0 to 72.6) 61.8 (37.3 to 79.1) 0.000
Ever smokers, n (%) 711 (65.4) 207 (76.7) 0.000
Packyears in ever smokers, median (range) 17.2 (0.1 to 117.1) 26.0 (0.6 to 262.2) 0.000
BMI
Normal weight, n (%) 284 (26.2) 65 (24.2)
Overweight, n (%) 540 (49.8) 139 (51.6)
Obese, n (%) 261 (24.0) 65 (24.2) 0.781
doi:10.1371/journal.pone.0058636.t001
Table 2. Distribution of genotypes and hazard ratio (HR) for all-cause mortality.
SNP Genotype Alive n=1,087
All-cause mortality
n=270 p value** HR (95% CI)*** p value
rs12778366* TT 798 (76.0) 220 (83.0) 1
TC+CC 252 (24.0) 45 (17.0) 0.015 0.69 (0.5020.96) 0.025
rs7069102 GG 449 (43.6) 124 (48.8) 1
GC 458 (44.5) 103 (40.6) 0.85 (0.6521.11) 0.234
CC 123 (11.9) 27 (10.6) 0.323 0.90 (0.5921.37) 0.628
rs2273773* TT 897 (81.1) 164 (76.6) 1
TC+CC 209 (18.9) 50 (23.4) 0.132 1.26 (0.9221.73) 0.155
*Due to the low frequency of individuals being homozygous for the minor allele heterozygotes and homozygotes variants were combined
**Differences in genotype distribution between alive subjects and those who died (excluding external causes of death) tested with x2 test
***Cox regression adjusted for age, gender and packyears at visit in 1989/90
doi:10.1371/journal.pone.0058636.t002
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Oral glucose tolerance test
In 1970/1972, 1973 and 1976 male subjects underwent the oral
glucose tolerance test (OGTT). They were given a drink of 100 g
glucose solution, and blood glucose was measured two hours later.
Statistical Analysis
Descriptive analyses of the subject characteristics were per-
formed using x2 tests for categorical variables and Mann-Whitney
U test for continuous variables (i.e. packyears in ever smokers and
age). The genotype frequencies were tested for Hardy-Weinberg
Equilibrium (HWE) by x2 analysis. Differences in genotype
distribution between dead and alive subjects were tested using x2
tests. SNP rs10823108 was tested in a general genetic model. Due
to the low frequency of individuals being homozygous for the
minor allele for rs12778366 (n= 14) and rs2273773 (n= 9)
heterozygotes and homozygotes for the minor allele were analyzed
in a one group. Cox proportional hazards regression models
adjusted for gender, age and packyears of smoking (all at the
survey in 1989/1990) were used to evaluate the association
between SNPs and all-cause mortality. Time was defined from the
examination in 1989/1990 until death, end of follow-up in 2008 or
last registration if subjects were lost to follow-up. Survival curves
are depicted based on these Cox models. Stratified analyses
according to gender, smoking habits (never smokers vs ever
smokers), BMI and age (dichotomized based on a median age at
visit in 1989/1990, i.e. 52 yrs) were performed. Subjects with BMI
$25 kg/m2 were categorized into the overweight/obese group
according to World Health Organization (WHO) criteria.
A linear regression model adjusted for age at the measurement
was used to evaluate the associations between SNPs in SIRT1 and
glucose tolerance.
P values ,0.05 were considered statistically significant (tested 2-
sided). All statistical analyses were performed using SPSS version
18.0 for Windows.
Results
Subjects with genetic data available and participating in the last
survey in 1989/1990 were included in this study (n = 1,390, see
Table 1). After 18 years of follow-up, 78.2% (n= 1,087) of the
cohort was still alive and 284 deaths (20.4%) were recorded. Out
of all deaths, 14 (4.9%) occurred due to external causes and these
were excluded form the analyses. Of the participants who had died
207 (76.7%) were ever smokers and these had significantly higher
numbers of packyears compared to participants still alive. It is
important to note that our study had an excellent follow-up rate,
since only 19 subjects (1.4%) could not be traced back.
The 3 tested SNPs (rs12778366, rs7069102 and rs2273773)
were in Hardy-Weinberg equilibrium. Among subjects who died,
83% had the wild type genotype of rs12778366 which is
significantly higher (p = 0.015) than the 76% in the subjects who
were still alive.
Cox regression showed that carriers of the minor allele of
rs12778366 had a significantly reduced risk of mortality compared
to wild types: HR 0.69 (95% CI: 0.50 to 0.96; p = 0.025; see
Table 2). Survival curves according to genotypes of rs12778366
clearly show the difference in mortality risk (Figure 1a). The same
directions of the effect of rs12778366 were observed within groups
that have different mortality risks, i.e. females (HR=0.82
(0.5021.35)) and males (HR=0.63 (0.4120.96)), never smokers
(HR=0.53 (0.2521.11)) and ever smokers (HR=0.75
(0.5221.08)), younger subjects (age # 52 yrs) (HR=0.68
(0.3021.54)) and older subjects (age . 52 yrs) (HR=0.69
(0.4820.98)), (Table 3 and Figure 1 b–c, e). Remarkably, the
protective effect of rs12778366 was observed in overweight/obese
subjects (HR=0.62 (0.4320.91)) but not in subjects with normal
weight (HR=0.95 (0.5021.80). The survival curves clearly show
that overweight/obese minor allele carriers of rs12778366 had
survival comparable to subjects with normal weight while
overweight/obese subjects with the wildtype genotype had an
increased mortality risk (Figure 1d). The 2 other SNPs did not
show significant associations between genotypes and mortality risk
(Table 2).
We analyzed the available data from 535 male subjects from the
current study (aged at the measurement 18–61 years) who
underwent the glucose tolerance test (OGTT). We found that
Figure 1. Survival curves for all-cause mortality according to SNP rs12778366. a. all subjects; b. stratified according to gender; c. stratified
according to smoking habits; d. stratified according to BMI; e. stratified according to age (median age at visit in 1989/1900). *the Y axis scale in a
figure 1e differs from Y axis scales in other figures.
doi:10.1371/journal.pone.0058636.g001
Table 3. HR for all-cause mortality for rs12778366 TC+CC
genotypes in stratified analysis.
Stratification HR (95% CI)** p value
a) gender
Females, n* = 653 0.82 (0.5021.35) 0.424
Males, n = 680 0.63 (0.4120.96) 0.032
b) smoking habits
Never smokers, n = 424 0.53 (0.2521.11) 0.092
Ever smokers, n = 909 0.75 (0.5221.08) 0.125
c) BMI
Normal weight, n = 344 0.95 (0.5021.80) 0.870
Overweight and obese, n = 987 0.62 (0.4320.91) 0.014
d) age
# 52 yrs, n = 670 0.68 (0.3021.54) 0.350
. 52 yrs, n = 663 0.69 (0.4820.98) 0.040
*n =number of all subjects included in the analysis (excluding those who died
due to external causes)
**rs12778366 TT genotype as a reference
doi:10.1371/journal.pone.0058636.t003
Table 4. Glucose levels (mmol/l) measured in males after the
oral glucose tolerance test (OGGT).
SNP Genotype n Mean (SD) B* (mmol/l) SE p value
rs12778366 TT 414 6.33 (1.55)
TC+CC 119 5.99 (1.22) 20.34 0.16 0.030
rs7069102 GG 229 6.33 (1.59)
GC 232 6.02 (1.43) 20.12 0.14 0.401
CC 59 6.32 (1.44) 0.02 0.22 0.931
rs2273773 TT 446 6.27 (1.51)
TC+CC 89 6.22 (1.44) 20.04 0.17 0.830
*Regression coefficient (B), its standard error (SE) and p value obtained with
linear regression analysis adjusted for age at the measurement.
doi:10.1371/journal.pone.0058636.t004
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the minor allele carriers of SNP rs12778366 had better glucose
tolerance, since they had a 0.34 mmol/l lower glucose levels
compared to wild type subjects (p = 0.03, see Table 4). When this
association was further investigated in subjects with normal weight
(n = 249) and overweight/obese subjects (n = 284) separately, we
found significantly better glucose tolerance in overweight/obese
carriers of the minor allele of rs12778366 (i.e. 0.60 mmol/l lower
glucose levels (p = 0.01)) compared to overweight/obese wild type
subjects. In subjects with normal weight the same direction was
observed (0.18 mmol/l lower glucose levels), but the effect was not
significant (p = 0.50).
Discussion
We found a 30% reduced mortality risk among minor allele
carriers of SNP rs12778366 in SIRT1, during a 18 years follow-up
study in the general population. Therefore, SIRT1 appears to be
an important candidate gene explaining individual differences in
human lifespan. There is evidence linking overexpression of Sir2
to extended lifespan in yeast, worms and flies [2–4]. Despite the
established role of mammalian SIRT1 in metabolism, genome
stability and stress response [30,31], polymorphisms in SIRT1
were not associated with exceptional human longevity in a cross-
sectional case-control study [22,24] nor with all-cause mortality in
a general population-based cohort [25] and in a group of over 85
years who were followed up until they died [23]. Whereas the last
study included only pre-selected old subjects the advantage of our
current study is that we did not use a selection criteria based on
age, but investigated the whole population in a longitudinal
manner. Actually, up till now, only one study in humans showed
associations between SIRT1 variants and healthy aging, what the
authors defined as being healthy (i.e. normal brain function and
verbal fluency test; laboratory findings for hemogram, peripheral
smear, urine, electrocytes, chest X-ray, kidney, pulmonary
function, echocardiography and ECG were normal) at the age
60 or higher [32]. In the light of recent uncertainty about the role
of sirtuins in longevity [1] our results importantly provide new
evidence in favor of a role of the gene in longevity.
We have shown an association between the SIRT1 gene and
long-term survival among minor allele carriers of SNP rs12778366
in SIRT1 in the total population. Furthermore, the directions of
the effect did not change in stratified analyses according to gender,
smoking habits and age. Interestingly, stratification according to
BMI showed the protective effect of rs1277836 only in
overweight/obese subjects. Taking into account the increased
mortality per se in obese subjects this finding may shed a new light
on obesity-related burdens.
One of the physiological pathways through which SIRT1 may
affect longevity might be glucose homeostasis. Indications
suggesting a role of this pathway were backed up by evidence
that minor allele carriers of SNP rs12778366 had better glucose
tolerance as determined by the oral glucose tolerance test.
Interestingly, stratified analysis according to BMI showed that
the effect was more pronounced in overweight/obese subjects,
whereas in subjects with normal weight only the direction of the
effect remained the same, but was not significant. In this light the
better glucose tolerance in overweight/obese minor allele carriers
of SNP rs12778366 could be considered a condition leading to
better survival in this group. This additional result emphasizes the
relevance of rs12778366 and indicates its possible use as a
screening tool for clinical purposes.
Previous studies indicate that transgenic mice that overexpress
SIRT1 appear to have beneficial phenotypes that may be relevant
in human health, including better glucose tolerance [33,34]. In
contrast to the positive effects of increased SIRT1 activity, SIRT1
deficiency impairs metabolism [35]. Therefore, we hypothesize
that variants in rs12778366 may lead to overexpression of the
protein, especially since this SNP is located in Transcription
Factor Binding Site (TFBS). Although rs12778366 is not
associated with the SIRT1 protein expression in adipose tissue,
lymphoblastoid cell lines and skin (Genevar (GENe Expression
VARiation) database) [36], this does not rule out a possible effect
of the SNP on protein expression in other tissues i.e. in the lung,
liver or heart, given the broad SIRT1 expression in humans.
Strengths and limitations
The major strength of the current study is the longitudinal
design. We were able to follow participants for 18 years, which
provided a wide time window for evaluating survival in the cohort.
A strength of our study is also the number of subjects (n = 1,390),
sampled from the general population. Additionally, the high
follow-up rate is a major strength of the study, since 98.6% of the
included subjects could be traced back. A limitation of our study is
the limited data on metabolic profile, because the oral glucose
tolerance test was performed only in male subjects and was not
accompanied by insulin measurements. Furthermore, the study
population consisted of white individuals of Dutch descent which
limits extrapolation to other ethnic groups.
In summary, this is the first study showing that SIRT1 plays a
role in human lifespan in a non-selected general population
cohort. The importance of SIRT1 is supported by the association
of its polymorphism with long-term survival in the general
population. Furthermore, linking SIRT1 polymorphisms to
improved glucose tolerance stresses the impact of SIRT1 on
metabolism in humans and identifies SIRT1 as a possible
candidate for therapeutic purposes.
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